Copyright
©The Author(s) 2022.
World J Clin Oncol. Jan 24, 2022; 13(1): 49-61
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
Table 5 Details of exposure for each patient with type of cancer and age at diagnosis of cancer
Disease | Genetic Diagnosis | Medication | Duration /mo | Dose/mg | Cancer type and stage | Age at diagnosis of cancer |
Ulcerative colitis | PMS2 | Ustekinumab, | 12 | Colon II | 19 | |
Golimumab | 6 | |||||
Vedolizumab | 24 | |||||
Crohn’s disease | MLH1 | 6MP | 24 | 50 | Colon I | 57 |
Crohn’s disease | PMS2 | Adalimumab | 18 | Colon III | 17 | |
Golimumab | 6 | |||||
Vedolizumab | 12 | |||||
Sarcoidosis | MLH1 | MTX | 60 | 15 | Renal I | 49 |
Rheumatoid arthritis | LLS | Etanercept | 120 | Breast I, Colon IV | 76 | |
Tofacitinib | 9 | |||||
MTX | 35 | 15 | ||||
Azathioprine | 72 | 50 | ||||
Rheumatoid arthritis | MSH2 | MTX | 4 | 20 | Colon II | 51 |
Rituximab | 72 | |||||
Psoriatic arthritis | MSI-H | Adalimumab | 36 | Colon III | 44 | |
Ustekinumab | 10 | |||||
MTX | 36 | 15 | ||||
Dermatomyositis | MSH2 | MTX | 12 | 15 | NA | NA |
Rheumatoid arthritis | MSI-H | MTX | 120 | 10 | NA | NA |
- Citation: Faisal MS, Burke CA, Liska D, Lightner AL, Leach B, O’Malley M, LaGuardia L, Click B, Achkar J, Kalady M, Church J, Mankaney G. Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. World J Clin Oncol 2022; 13(1): 49-61
- URL: https://www.wjgnet.com/2218-4333/full/v13/i1/49.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i1.49